Fluorine‐18 labelling of oligonucleotides: Prosthetic labelling at the 5′‐end using the N‐(4‐[18F]fluorobenzyl)‐2‐bromoacetamide reagent
暂无分享,去创建一个
[1] C. Crouzel,et al. General method to label antisense oligonucleotides with radioactive halogens for pharmacological and imaging studies. , 2000, Bioconjugate chemistry.
[2] C. Crouzel,et al. Fluorine-18 labeling of oligonucleotides bearing chemically—modified ribose—phosphate backbones , 2000 .
[3] C Crouzel,et al. Synthesis and nicotinic acetylcholine receptor in vivo binding properties of 2-fluoro-3-[2(S)-2-azetidinylmethoxy]pyridine: a new positron emission tomography ligand for nicotinic receptors. , 1999, Journal of medicinal chemistry.
[4] C. Crouzel,et al. Synthesis of a fluorine-18 labeled derivative of epibatidine for in vivo nicotinic acetylcholine receptor PET imaging. , 1999, Bioorganic & medicinal chemistry.
[5] Bernard Bendriem,et al. In vivo imaging of oligonucleotides with positron emission tomography , 1998, Nature Medicine.
[6] M. Caruthers,et al. Comparative pharmacokinetics, tissue distribution, and tumor accumulation of phosphorothioate, phosphorodithioate, and methylphosphonate oligonucleotides in nude mice. , 1997, Antisense & nucleic acid drug development.
[7] C. Crouzel,et al. A general method for labeling oligodeoxynucleotides with 18F for in vivo PET imaging , 1997 .
[8] P. D. Cook,et al. Evaluation of 2'-modified oligonucleotides containing 2'-deoxy gaps as antisense inhibitors of gene expression. , 1993, The Journal of biological chemistry.
[9] P. Miller. Oligonucleoside Methylphosphonates as Antisense Reagents , 1991, Bio/Technology.
[10] K. Hamacher,et al. Efficient stereospecific synthesis of no-carrier-added 2-[18F]-fluoro-2-deoxy-D-glucose using aminopolyether supported nucleophilic substitution. , 1986, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[11] S. Agrawal,et al. Pharmacokinetics of Antisense Oligonucleotides , 1995, Clinical pharmacokinetics.